Left with eight overs to survive, Lancashire ended the day on 16 for 3, Keaton Jennings having been bowled between bat and ...

and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Vertex Pharmaceuticals is throwing in the towel on its investigational type 1 diabetes islet cell-device combination VX-264 after it failed to increase C-peptide in a 90-day study. Combination ...

Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX-880) ...

Vertex will not advance VX-264 further in clinical trials. Credit: Andrii Yalanskyi via Getty Images. Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell ...

Saturday has been declared WFAA Weather Alert Days by the WFAA Weather Team. Scattered storms have moved through the DFW area in multiple rounds this week with a couple more rounds to go. While ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement. There were two primary endpoints in ...